Pain News and Research

Latest Pain News and Research

Methodist surgeons perform multiple cardiac vessel bypasses through small single incision

Surgeons at the Methodist DeBakey Heart & Vascular Center perform multiple cardiac vessel bypasses through a single, small incision in the patient's side, reducing pain, recovery time and risk for infection.

15 Sep 2010

FDA grants Arcion's ARC-4558 Fast Track designation for pain involved in Painful Diabetic Neuropathy

Arcion Therapeutics, a venture backed clinical stage biotechnology company developing topical therapies for chronic pain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARC-4558 for the treatment of pain associated with Painful Diabetic Neuropathy (PDN).

15 Sep 2010

PLX-PAD therapy improves quality of life in CLI patients

Pluristem Therapeutics Inc. today reported that data from clinical trials show the Company's placenta-derived cell therapy, PLX-PAD, is safe and improves quality of life as well as other efficacy measurements in patients with Critical Limb Ischemia (CLI), the end-stage of Peripheral Artery Disease (PAD).

15 Sep 2010

Aspirin can prevent stroke and heart attacks: Study

In a large scale Australian study, researchers have found that Aspirin can save lives and drastically reduce rates of stroke and heart attack.

15 Sep 2010

FDA approves Krystexxa drug to treat gout

The U.S. Food and Drug Administration approved Krystexxa (pegloticase) to treat the painful condition known as gout in adults who do not respond to or who cannot tolerate conventional therapy.

15 Sep 2010

Stroke risk with common pain killers dismissed by manufacturer

An eight-year Danish study, which involved more than 2.5 million healthy Danes found there was a higher risk of stroke for those taking high doses of ibuprofen, which is in the painkiller Nurofen. The manufacturers of Nurofen, Reckitt Benckiser, have dismissed these reports. The spokesperson for the company said, “it is important to note that the conclusions drawn by the study authors are based on high doses of ibuprofen…The results of this study should not be confused with non-prescription low doses of NSAIDs, such as ibuprofen, which are available over-the-counter and used by millions of people around the world, for short periods of time, every day.”

14 Sep 2010

Cetaphil launches Restoraderm for management of eczema and atopic dermatitis skin

The Cetaphil® brand, the #1 dermatologist-recommended brand of cleansers and moisturizers announced the launch of Cetaphil® Restoraderm® products, formulated specifically for the needs of eczema and atopic dermatitis skin. Cetaphil® Restoraderm® Skin Restoring Body Wash and Skin Restoring Moisturizer soothes itching associated with skin affected by eczema and atopic dermatitis.

14 Sep 2010

AstraZeneca Chief Scientist shares enthusiasm for collaborative clinical research

The pharmaceutical industry must ensure an improved record of delivery by providing high quality, cost effective solutions to well defined unmet needs. This can be achieved through strategic collaborations that strengthen disease knowledge and provide improved tools to strengthen therapeutic target validation and to monitor therapeutic efficacy, says Andy Dray, Chief Scientist at AstraZeneca.

14 Sep 2010

World Congress on Arthrosis to take place in Belgium from September 23 to 26, 2010

Over a 1000 experts from the world will participate in the Osteoarthritis Research Society International (OARSI) congress, under the Presidency of the Belgian Professor Yves Henrotin (University of Liège).

14 Sep 2010

Emergency physicians to present research studies at Research Forum 2010

The risks associated with boarding admitted patients in the emergency department – including patient mortality – as well as proposed solutions will be key themes of Scientific Assembly, the annual meeting of the American College of Emergency Physicians. In addition, emergency physicians will present more than 450 research studies during 2010 Research Forum, the premier, annual scientific research event focused on the latest advances in the practice of emergency medicine.

14 Sep 2010

RS Medical receives Federal Supply Schedule contract

International Rehabilitative Sciences, Inc. d/b/a RS Medical, announced today its first award of a Federal Supply Schedule contract. The contract is in effect through June 14, 2015.

14 Sep 2010

$Bisphosphonates drug may lead to atypical femur fractures in osteoporosis patients: Report$

Bisphosphonates drug may lead to atypical femur fractures in osteoporosis patients: Report

A widely prescribed class of drugs is highly effective in reducing common bone fractures in people with osteoporosis, but an expert panel announced today that these same drugs - when used long term - may be related to unusual but serious fractures of the thigh bone.

14 Sep 2010

Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation

A study evaluating the level of platelet aggregation achieved after switching from Plavix (clopidogrel) 75 mg once-daily maintenance dosing plus aspirin to Effient(prasugrel) 10 mg once-daily maintenance dosing (MD) in patients with acute coronary syndrome (ACS) was published today in the Journal of the American College of Cardiology.

14 Sep 2010

Ironwood, Forest Laboratories announce positive results for linaclotide Phase 3 clinical trials in IBS-C patients

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line results from the first of two Phase 3 clinical trials assessing the efficacy and safety of the investigational drug, linaclotide, in patients with irritable bowel syndrome with constipation (IBS-C).

14 Sep 2010

SpineAlign commences enrollment in European Observational Registry for VerteLift System

SpineAlign Medical, Inc. announced today that it has enrolled its initial patient in the European Observational Registry for the VerteLift System, an observation study to further assess the ability of the VerteLift System to treat the pain and dysfunction associated with osteoporotic vertebral compression fractures (VCF), while providing clinically measurable height restoration based upon previous European experience and analysis.

13 Sep 2010

Less-invasive alternative to vasectomy

Pro-Vas® – the new faster, less-invasive alternative to traditional vasectomy – was featured Thursday in millions of homes and doctors' offices across the nation on "The Doctors" TV show. This nationally syndicated show highlights significant advancements in the world of health and medicine.

13 Sep 2010

Defining best practices in palliative care in Europe

Palliative care is not just about pain relief, albeit an important component, but embraces a wide range of patient care, with the aim of improving the quality of a patient's life and upholding his or her sense of dignity. Palliative care - not to be confused with 'care at any cost'- implies the involvement of patients' families, as active caregivers as well as people to take care of: their quality of life is also a primary objective.

13 Sep 2010

Fusion surgery for spondylolisthesis in lumbar spine has long-term benefits: Study

A group of children who underwent fusion surgery for spondylolisthesis in the lumbar spine 30 years ago showed a clear reduction in back pain when followed up seven years later. A new study of these patients as adults has found that the benefits have lasted, reveals research from the Sahlgrenska Academy and Sahlgrenska University Hospital presented this week at the International Society of Orthopaedic Surgery and Traumatology (SICOT) annual international conference in Gothenburg.

13 Sep 2010

Ranier's Cadisc-L spinal disc replacement granted CE Mark Approval

Ranier Technology, the medical device development company focusing on the commercialisation of spinal implants, has announced that it has received CE Mark approval for its Cadisc™-L; an elasto-mimetic spinal disc replacement device for the lumbar spine. The CE Mark approval was received following a review of the company's multi-centre European clinical study and its extensive portfolio of biocompatibility and biomechanical testing.

13 Sep 2010

Diamyd Medical reports potential results on NP2 Phase I clinical trial for chronic pain

Diamyd Medical AB, to date no drug related Serious Adverse Events have been reported by any patient included in Diamyd's Phase I clinical trial investigating NP2 as a potential therapy for chronic pain. Based upon the Phase I findings to date, the company is planning a multi-center, randomized, double-blind, placebo controlled Phase II clinical trial with NP2 in the United States.

13 Sep 2010

Pain News and Research

Latest Pain News and Research

Methodist surgeons perform multiple cardiac vessel bypasses through small single incision

FDA grants Arcion's ARC-4558 Fast Track designation for pain involved in Painful Diabetic Neuropathy

PLX-PAD therapy improves quality of life in CLI patients

Aspirin can prevent stroke and heart attacks: Study

FDA approves Krystexxa drug to treat gout

Stroke risk with common pain killers dismissed by manufacturer

Cetaphil launches Restoraderm for management of eczema and atopic dermatitis skin

AstraZeneca Chief Scientist shares enthusiasm for collaborative clinical research

World Congress on Arthrosis to take place in Belgium from September 23 to 26, 2010

Emergency physicians to present research studies at Research Forum 2010

RS Medical receives Federal Supply Schedule contract

Bisphosphonates drug may lead to atypical femur fractures in osteoporosis patients: Report

Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation

Ironwood, Forest Laboratories announce positive results for linaclotide Phase 3 clinical trials in IBS-C patients

SpineAlign commences enrollment in European Observational Registry for VerteLift System

Less-invasive alternative to vasectomy

Defining best practices in palliative care in Europe

Fusion surgery for spondylolisthesis in lumbar spine has long-term benefits: Study

Ranier's Cadisc-L spinal disc replacement granted CE Mark Approval

Diamyd Medical reports potential results on NP2 Phase I clinical trial for chronic pain

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Pain News and Research

Latest Pain News and Research

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in